These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 20609694

  • 1. The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol.
    Giles TD.
    Am J Med; 2010 Jul; 123(7 Suppl 1):S16-20. PubMed ID: 20609694
    [Abstract] [Full Text] [Related]

  • 2. Nebivolol: a review.
    Cockcroft J.
    Expert Opin Pharmacother; 2004 Apr; 5(4):893-9. PubMed ID: 15102571
    [Abstract] [Full Text] [Related]

  • 3. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.
    Bakris GL, Basile JN, Giles TD, Taylor AA.
    Am J Med; 2010 Jul; 123(7 Suppl 1):S2-8. PubMed ID: 20609695
    [Abstract] [Full Text] [Related]

  • 4. Nebivolol: third-generation beta-blockade.
    de Boer RA, Voors AA, van Veldhuisen DJ.
    Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
    [Abstract] [Full Text] [Related]

  • 5. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM, Antonucci G, Conte M, Di Pumpo M, Giancola A, Antonucci E.
    Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394
    [Abstract] [Full Text] [Related]

  • 6. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE, DiGennaro F, Giani JF, Dominici FP.
    Vasc Health Risk Manag; 2012 Jul; 8():151-60. PubMed ID: 22454559
    [Abstract] [Full Text] [Related]

  • 7. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
    Sica DA, Black HR.
    Curr Hypertens Rep; 2008 Aug; 10(4):330-5. PubMed ID: 18625165
    [Abstract] [Full Text] [Related]

  • 8. Arterial stiffness, hypertension, and rational use of nebivolol.
    Agabiti-Rosei E, Porteri E, Rizzoni D.
    Vasc Health Risk Manag; 2009 Aug; 5(1):353-60. PubMed ID: 19475771
    [Abstract] [Full Text] [Related]

  • 9. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H, Lavie CJ, Ventura HO.
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and tolerability of nebivolol in hypertensive African American patients.
    Saunders E, Smith WB, DeSalvo KB, Sullivan WA.
    J Clin Hypertens (Greenwich); 2007 Nov; 9(11):866-75. PubMed ID: 17978594
    [Abstract] [Full Text] [Related]

  • 11. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L.
    Drugs; 2010 Nov; 70(1):41-56. PubMed ID: 20030424
    [Abstract] [Full Text] [Related]

  • 12. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S, Galdames K, Noriega V, Miranda HF.
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [Abstract] [Full Text] [Related]

  • 13. Beta-blockers in the treatment of hypertension: new data, new directions.
    Weber MA, Bakris GL, Giles TD, Messerli FH.
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):234-8. PubMed ID: 18326967
    [No Abstract] [Full Text] [Related]

  • 14. Realities of newer beta-blockers for the management of hypertension.
    Manrique C, Giles TD, Ferdinand KC, Sowers JR.
    J Clin Hypertens (Greenwich); 2009 Jul; 11(7):369-75. PubMed ID: 19583633
    [Abstract] [Full Text] [Related]

  • 15. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
    Moen MD, Wagstaff AJ.
    Drugs; 2006 Jul; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
    [Abstract] [Full Text] [Related]

  • 16. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D, Papademetriou V.
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
    [Abstract] [Full Text] [Related]

  • 17. One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk.
    Basile JN.
    Am J Med; 2010 Jul; 123(7 Suppl 1):S9-15. PubMed ID: 20609697
    [Abstract] [Full Text] [Related]

  • 18. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient.
    Cockcroft J.
    Vasc Health Risk Manag; 2007 Jul; 3(6):909-17. PubMed ID: 18200810
    [Abstract] [Full Text] [Related]

  • 19. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE, Philipp T.
    Dtsch Med Wochenschr; 2006 Nov 10; 131(45):2545-50. PubMed ID: 17091442
    [Abstract] [Full Text] [Related]

  • 20. [Vasodilating beta blockers as effective antihypertensive agents. Results of a multicenter observational study].
    von Fallois J, Faulhaber HD.
    MMW Fortschr Med; 2000 Jun 15; 142(24):45. PubMed ID: 10895582
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.